JP2024544538A5 - - Google Patents

Info

Publication number
JP2024544538A5
JP2024544538A5 JP2024527603A JP2024527603A JP2024544538A5 JP 2024544538 A5 JP2024544538 A5 JP 2024544538A5 JP 2024527603 A JP2024527603 A JP 2024527603A JP 2024527603 A JP2024527603 A JP 2024527603A JP 2024544538 A5 JP2024544538 A5 JP 2024544538A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
approximately
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/131297 external-priority patent/WO2023083288A1/en
Publication of JP2024544538A publication Critical patent/JP2024544538A/ja
Publication of JP2024544538A5 publication Critical patent/JP2024544538A5/ja
Pending legal-status Critical Current

Links

JP2024527603A 2021-11-11 2022-11-11 THR-βアゴニストによる肝障害の治療 Pending JP2024544538A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CNPCT/CN2021/130083 2021-11-11
CNPCT/CN2022/097426 2022-06-07
CN2022097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (2)

Publication Number Publication Date
JP2024544538A JP2024544538A (ja) 2024-12-03
JP2024544538A5 true JP2024544538A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527603A Pending JP2024544538A (ja) 2021-11-11 2022-11-11 THR-βアゴニストによる肝障害の治療

Country Status (14)

Country Link
US (1) US20240293416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544538A (cg-RX-API-DMAC7.html)
KR (1) KR20240101642A (cg-RX-API-DMAC7.html)
CN (1) CN118871113A (cg-RX-API-DMAC7.html)
AU (1) AU2022388507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238108A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007225A2 (cg-RX-API-DMAC7.html)
IL (1) IL312637A (cg-RX-API-DMAC7.html)
MX (1) MX2024005647A (cg-RX-API-DMAC7.html)
PE (1) PE20241327A1 (cg-RX-API-DMAC7.html)
TW (1) TW202332447A (cg-RX-API-DMAC7.html)
WO (1) WO2023083288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CN121081472A (zh) * 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2019515884A5 (cg-RX-API-DMAC7.html)
JP2024071370A5 (cg-RX-API-DMAC7.html)
EP2429986B1 (en) Haloalkyl heteroaryl benzamide compounds
EP4635972A3 (en) Functionalized peptides as antiviral agents
JP4542743B2 (ja) ピリドン誘導体の溶液状医薬組成物
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2009102342A5 (cg-RX-API-DMAC7.html)
JP2023504415A5 (cg-RX-API-DMAC7.html)
JP2003509349A5 (cg-RX-API-DMAC7.html)
JP2017513824A5 (cg-RX-API-DMAC7.html)
JP2023525571A5 (cg-RX-API-DMAC7.html)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2024531188A5 (cg-RX-API-DMAC7.html)
JPWO2023054732A5 (cg-RX-API-DMAC7.html)
JP2023500060A5 (cg-RX-API-DMAC7.html)
JP2009513713A5 (cg-RX-API-DMAC7.html)
JP2022527401A5 (cg-RX-API-DMAC7.html)
JP2020510085A5 (cg-RX-API-DMAC7.html)
JP2023500685A5 (cg-RX-API-DMAC7.html)
MX2026001663A (es) Formulaciones farmaceuticas de agonistas de gpr119 y usos de estas
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2022503733A5 (cg-RX-API-DMAC7.html)